Biotech Downgrades Hit Ultragenyx on Trial Failure, Moderna on Valuation
Evercore ISI cut its rating on Ultragenyx after a failed trial while Rothschild Redburn downgraded Moderna over how the stock is priced.
Two separate analyst downgrades hit biotech stocks, with Ultragenyx cut on a clinical trial failure and Moderna cut on valuation grounds.
BREAKING STORYBEARISH